On June 24, 2019 Amplia Therapeutics (ASX: ATX) is reported the appointment of Dr John Lambert as Chief Executive Officer (Press release, Amplia Therapeutics, JUN 24, 2019, View Source;[email protected] [SID1234537229]). Long serving former CEO, Mr Simon Wilkinson, will remain on the Company’s Board as a non-executive director.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based in Melbourne, Dr Lambert has worked in drug discovery and development for over 20 years. His previous roles have included senior management positions at Biota Holdings Limited and Medicines Development for Global Health. His experience spans the full drug development lifecycle from early discovery, intellectual property protection, licensing, product development, and regulatory approval. John has been Amplia’s Operations Manager since August 2018 and has been directing all aspects of the Company’s clinical enabling work since that time.
"The appointment of Dr Lambert as Chief Executive is another important step in the transformation of Amplia" said Chairman Dr Warwick Tong. "John’s experience and enthusiasm make him the ideal candidate to deliver the near and medium term clinical development milestones we have set for the Company".
The Board of Amplia acknowledges the hard work and dedication of outgoing CEO Simon Wilkinson. "Mr Wilkinson has been a great champion for our Company for many years and we are especially pleased that he will be continuing as a director to ensure a smooth transition for Dr Lambert" said Dr Tong.
Dr Lambert commented "I am delighted to take up the Chief Executive role at Amplia Therapeutics. I’m particularly excited to be working alongside a Board with so much industry experience and I am looking forward to working with them to deliver on our objectives and drive value for our shareholders."
For Further Information
Dr Warwick Tong, Chairman
+61 450 296 930
www.ampliatx.com
Details of Dr Lambert’s remuneration as CEO follow.